Table 2.
Treatment recommendations in chronic hepatitis B virus and hepatitis D virus coinfection
| HDV RNA | ALT | HBV DNA | Cirrhosis | Treatment |
|---|---|---|---|---|
| + | + | <2000 IU/mL | No | IFN alone |
| + | + | >2000 IU/mL | No | IFN + NA |
| + | + | <2000 IU/mL | Yes | IFN + NA |
| + | + | >2000 IU/mL | Yes | IFN + NA |
IFN treatment for 48 weeks: Peg-IFN-α-2a (Pegasys) 180 μg weekly; Peg-IFN-α-2b (PegIntron) 1.5 μg/kg weekly.
NA treatment: entecavir (Baraclude) 0.5 to 1 mg daily; tenofovir dipovoxil fumarate (Viread) 300 mg daily; tenofovir alafenamide (Vemlidy) 25 mg daily.
Abbreviations: ALT, alanine transaminase; NA, nucleotide or nucleoside analogue.